NSPR CGuard EPS Carotid Stent Platform 2023

Nspr presents its CGuard EPS carotid stent platform leveraging proprietary MicroNet technology for stroke prevention and carotid artery disease treatment. The deck highlights clinical outcomes across 9 trials and 1,850+ patients, market expansion in 30 countries, and anticipated FDA approval in Q1 2025. Company achieved CMS reimbursement approval and closed $113.6M financing to advance commercialization and US regulatory milestones.